| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.6 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |